Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma

Véronique Béréziat (1, 2) , Christelle Mazurier (1) , Martine Auclair (1, 2) , Nathalie Ferrand (1) , Séverine Jolly (1) , Tiffany Marie (1) , Ladan Kobari (1) , Indira Toillon (1, 2) , François Delhommeau (1) , Bruno Fève (3, 1, 2) , Annette K Larsen (1) , Michèle Sabbah (1) , Laurent Garderet (1, 3)

1 CRSA - Centre de Recherche Saint-Antoine
2 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
3 CHU Saint-Antoine [AP-HP]

Multiple myeloma is characterized by bone lesions linked to increased osteoclast and decreased osteoblast activities. In particular, the osteoblast differentiation of bone marrow-derived stem cells (MSC) is impaired. Among the potential therapeutic tools for counteracting bone lesions, adipose-derived stem cells (ASC) could represent an appealing source for regenerative medicine due to their similar characteristics with MSC. Our study is among the first giving detailed insights into the osteoblastogenic capacities of ASC isolated by fat aspiration from myeloma patients (MM-ASC) compared to healthy subjects (HD-ASC). We showed that MM-ASC and HD-ASC exhibited comparable morphology, proliferative capacity, and immunophenotype. Unexpectedly, although normal in adipocyte differentiation, MM-ASC present a defective osteoblast differentiation, as indicated by less calcium deposition, decreased alkaline phosphatase activity, and downregulation of RUNX2 and osteocalcin. Furthermore, these ASC-derived osteoblasts displayed enhanced senescence, as shown by an increased β-galactosidase activity and cell cycle inhibitors expression (p16INK4A, p21WAF1/CIP1.), associated with a markedly increased expression of DKK1, a major inhibitor of osteoblastogenesis in multiple myeloma. Interestingly, inhibition of DKK1 attenuated senescence and rescued osteoblast differentiation, highlighting its key role. Our findings show, for the first time, that multiple myeloma is a systemic disease and suggest that ASC from patients would be unsuitable for tissue engineering designed to treat myeloma-associated bone disease.

Mots clés: multiple myeloma; bone disease; osteogenesis; adipogenesis; adipose-derived stem cells; bone marrow; senescence; Dickkopf-related protein 1; systemic disease

Domaines: Cancer; Organisation et fonctions cellulaires [q-bio.SC]; Hématologie

Véronique Béréziat, Christelle Mazurier, Martine Auclair, Nathalie Ferrand, Séverine Jolly, et al.. Systemic Dysfunction of Osteoblast Differentiation in Adipose-Derived Stem Cells from Patients with Multiple Myeloma. Cells, 2019, 8 (5), pp.441. ⟨10.3390/cells8050441⟩. ⟨hal-02165707⟩